Jetrea ocriplasmin regulatory update

On Dec. 27, 2013, ThromboGenics said the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended reimbursing Jetrea ocriplasmin from ThromboGenics to treat symptomatic vitreomacular adhesion (VMA), a precursor to vitreomacular traction (VMT). The CADTH makes recommendations to provincial and other drug plans through the Common Drug Review. All provinces except Quebec participate in the review. ...